Why take two pills when you can just take one? Welcome to the latest phenomenon in healthcare: combination pills. Tim Walbert, president and chief executive officer of Horizon Therapeutics, tells host Bruce Japsen about the drug industry's push toward combining two or more treatments into one pill, and the potential benefits for us and for our patients.
Drugmakers' Foray into the Combination Pill Market
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Why take two pills when you can just take one? Welcome to the latest phenomenon in healthcare: combination pills. Tim Walbert, president and chief executive officer of Horizon Therapeutics, tells host Bruce Japsen about the drug industry's push toward combining two or more treatments into one pill, and the potential benefits for us and for our patients.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
HF Management for Patients with Comorbid Conditions
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?